Ethnic variation in response to EGFR inhibitors
Publication in refereed journal


香港中文大学研究人员 ( 现职)

莫树锦教授 (肿瘤学系)

全文

数位物件识别号 (DOI) http://dx.doi.org/10.1016/j.ddstr.2011.04.003

引用次数
Scopushttp://aims.cuhk.edu.hk/converis/portal/Publication/0Scopus source URL

其它资讯

摘要Most patients with non-small-cell lung cancer present with advanced stage disease, for which standard therapy would be a platinum-based doublet combination. Novel targeted therapies that interfere with specific molecular signaling pathways have emerged as a new standard option for selected patients with epidermal growth factor receptor (EGFR) mutation. Clinical trials have demonstrated significant ethnic variation in tumor response to EGFR tyrosine kinase inhibitors (TKIs) and incidence of EGFR mutations, with a significantly higher incidence of activated EGFR mutation in Asia. This review discusses the variations and the implications for treatment. ? 2http://aims.cuhk.edu.hk/converis/portal/Publication/012 Elsevier Ltd. All rights reserved.

着者Loong H.H., Wei J., Mok T.S.
期刊名称Drug Discovery Today: Therapeutic Strategies
出版年份2http://aims.cuhk.edu.hk/converis/portal/Publication/012
月份9
日期1
卷号9
期次2-3
出版社Elsevier BV
出版地Netherlands
国际标準期刊号174http://aims.cuhk.edu.hk/converis/portal/Publication/0-6773
语言英式英语